Cabotegravir/rilpivirine (Cabenuva) vs Dolutegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Cabotegravir/rilpivirine (Cabenuva)

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Weak signal

NCT05917509 · Phase 3 · completed

The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2027 · NCT06411223 (registry estimate)

Reported efficacy

Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)

Result source: NCT03299049

Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)

Marketed by GlaxoSmithKline and partners

Approved in HIVsmall molecule
Reliable signal

NCT01263015 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled phase 3 trial in 833 participants comparing dolutegravir plus abacavir/lamivudine to Atripla. The primary endpoint of virologic suppression (<50 copies/mL) at week 48 was a hard clinical measure, and the comparison was statistically significant in favor of dolutegravir (88% vs 81%, p=0.003), with the confidence interval excluding zero. The trial was adequately powered and the primary outcome was met, supporting a strong evidence grade.

Next expected readout: November 2026 · NCT04892654 (registry estimate)

Reported efficacy

Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). (met)

Result source: NCT01263015

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCabotegravir/​rilpivirine (Cabenuva)Dolutegravir
HIV-1 RNA below 50 copies/mL (week 48)94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
88% vs 85%vs RTG50 mg Once a Day · wk 48 · n 411NCT01227824
12 other results
  • 90% vs 83% 50 mg once daily · wk 48 · n 242 · Phase 3 · primary NCT01449929
  • 88% vs 81% 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · primary NCT01263015
  • 90% vs 93% wk 48 · n 356 · Phase 3 · primary NCT02831673
  • 93% vs 94% wk 48 · n 360 · Phase 3 · primary NCT02831764
  • 71% vs 63% 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 77% vs 70% 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 79% vs 83% wk 144 · n 356 · Phase 3 · secondary NCT02831673
  • 84% vs 84% wk 144 · n 360 · Phase 3 · secondary NCT02831764
  • 84% vs 89% wk 96 · n 356 · Phase 3 · secondary NCT02831673
  • 88% vs 90% wk 96 · n 360 · Phase 3 · secondary NCT02831764
  • 92% vs 93% wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 94% vs 94% wk 24 · n 360 · Phase 3 · secondary NCT02831764
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311—Not posted · NCT01837277
CD4 count, change (week 48)270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
163 vs 174−11 vs placebo50 mg BID · wk 72 · n 14NCT01568892
44 other results
  • 170 vs 146 50 mg BID · wk 60 · n 14 · Phase 3 · secondary NCT01568892
  • 115 vs 156 50 mg BID · wk 48 · n 14 · Phase 3 · secondary NCT01568892
  • 90.5 vs 125.5 50 mg BID · wk 40 · n 14 · Phase 3 · secondary NCT01568892
  • 48 vs 135.5 50 mg BID · wk 32 · n 14 · Phase 3 · secondary NCT01568892
  • 39 vs 117 50 mg BID · wk 24 · n 14 · Phase 3 · secondary NCT01568892
  • 292.2 vs 286.2 50 mg Once a Day · wk 96 · n 411 · Phase 3 · secondary NCT01227824
  • 281.3 vs 292.9 50 mg Once a Day · wk 84 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 278.6 50 mg Once a Day · wk 72 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 264.2 50 mg Once a Day · wk 60 · n 411 · Phase 3 · secondary NCT01227824
  • 238.9 vs 257.5 50 mg Once a Day · wk 48 · n 411 · Phase 3 · secondary NCT01227824
  • 248.8 vs 230.7 wk 48 · n 248 · Phase 3 · secondary NCT01910402
  • 224.1 vs 239.8 50 mg Once a Day · wk 40 · n 411 · Phase 3 · secondary NCT01227824
  • 230.7 vs 191.4 wk 36 · n 248 · Phase 3 · secondary NCT01910402
  • 223.4 vs 241.3 50 mg Once a Day · wk 32 · n 411 · Phase 3 · secondary NCT01227824
  • 199.3 vs 204.2 50 mg Once a Day · wk 24 · n 411 · Phase 3 · secondary NCT01227824
  • 200.6 vs 163 wk 24 · n 248 · Phase 3 · secondary NCT01910402
  • 322.6 vs 286 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 315.2 vs 272.1 50 mg plus 600/300 mg once daily · wk 84 · n 414 · Phase 3 · secondary NCT01263015
  • 349.3 vs 298.9 50 mg plus 600/300 mg once daily · wk 108 · n 414 · Phase 3 · secondary NCT01263015
  • 306.1 vs 269.6 50 mg plus 600/300 mg once daily · wk 72 · n 414 · Phase 3 · secondary NCT01263015
  • 347 vs 311 50 mg plus 600/300 mg once daily · wk 120 · n 414 · Phase 3 · secondary NCT01263015
  • 271.3 vs 235.3 50 mg plus 600/300 mg once daily · wk 60 · n 414 · Phase 3 · secondary NCT01263015
  • 377.9 vs 327.2 50 mg plus 600/300 mg once daily · wk 132 · n 414 · Phase 3 · secondary NCT01263015
  • 378.5 vs 331.6 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 267.5 vs 209.5 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · secondary NCT01263015
  • 379.5 vs 333.3 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 265.5 vs 216.2 50 mg plus 600/300 mg once daily · wk 40 · n 414 · Phase 3 · secondary NCT01263015
  • 250.5 vs 208.1 50 mg plus 600/300 mg once daily · wk 32 · n 414 · Phase 3 · secondary NCT01263015
  • 216.9 vs 177.8 50 mg plus 600/300 mg once daily · wk 24 · n 414 · Phase 3 · secondary NCT01263015
  • 264.7 vs 253.8 wk 96 · n 301 · Phase 3 · secondary NCT02831673
  • 272 vs 264.6 wk 96 · n 318 · Phase 3 · secondary NCT02831764
  • 265 vs 230 wk 96 · n 350 · Phase 2/3 · secondary NCT02259127
  • 311 vs 230 wk 96 · n 154 · Phase 2/3 · secondary NCT02259127
  • 228 vs 230 wk 96 · n 196 · Phase 2/3 · secondary NCT02259127
  • 222.2 vs 217.7 wk 48 · n 356 · Phase 3 · secondary NCT02831673
  • 301.8 vs 303.2 wk 144 · n 270 · Phase 3 · secondary NCT02831673
  • 225.7 vs 217.2 wk 48 · n 360 · Phase 3 · secondary NCT02831764
  • 301.7 vs 296.6 wk 144 · n 296 · Phase 3 · secondary NCT02831764
  • 192.2 vs 175.1 wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 188.8 vs 163.2 wk 24 · n 360 · Phase 3 · secondary NCT02831764
  • 72 vs 230 wk 96 · n 42 · Phase 2/3 · secondary NCT02259127
  • 39 vs 28 wk 48 · n 40 · Phase 3 · secondary NCT02263326
  • 88 vs 75 wk 24 · n 65 · Phase 2 · secondary NCT03991013
  • 111 vs 101 wk 24 · n 52 · Phase 2 · secondary NCT03851588

HIV-1 RNA below 50 copies/mL (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
Dolutegravir
88% vs 85%vs RTG50 mg Once a Day · wk 48 · n 411NCT01227824
12 other results
  • 90% vs 83% 50 mg once daily · wk 48 · n 242 · Phase 3 · primary NCT01449929
  • 88% vs 81% 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · primary NCT01263015
  • 90% vs 93% wk 48 · n 356 · Phase 3 · primary NCT02831673
  • 93% vs 94% wk 48 · n 360 · Phase 3 · primary NCT02831764
  • 71% vs 63% 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 77% vs 70% 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 79% vs 83% wk 144 · n 356 · Phase 3 · secondary NCT02831673
  • 84% vs 84% wk 144 · n 360 · Phase 3 · secondary NCT02831764
  • 84% vs 89% wk 96 · n 356 · Phase 3 · secondary NCT02831673
  • 88% vs 90% wk 96 · n 360 · Phase 3 · secondary NCT02831764
  • 92% vs 93% wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 94% vs 94% wk 24 · n 360 · Phase 3 · secondary NCT02831764

HIV-1 RNA 50 copies/mL or more (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311
Dolutegravir
—Not posted · NCT01837277

CD4 count, change (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
Dolutegravir
163 vs 174−11 vs placebo50 mg BID · wk 72 · n 14NCT01568892
44 other results
  • 170 vs 146 50 mg BID · wk 60 · n 14 · Phase 3 · secondary NCT01568892
  • 115 vs 156 50 mg BID · wk 48 · n 14 · Phase 3 · secondary NCT01568892
  • 90.5 vs 125.5 50 mg BID · wk 40 · n 14 · Phase 3 · secondary NCT01568892
  • 48 vs 135.5 50 mg BID · wk 32 · n 14 · Phase 3 · secondary NCT01568892
  • 39 vs 117 50 mg BID · wk 24 · n 14 · Phase 3 · secondary NCT01568892
  • 292.2 vs 286.2 50 mg Once a Day · wk 96 · n 411 · Phase 3 · secondary NCT01227824
  • 281.3 vs 292.9 50 mg Once a Day · wk 84 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 278.6 50 mg Once a Day · wk 72 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 264.2 50 mg Once a Day · wk 60 · n 411 · Phase 3 · secondary NCT01227824
  • 238.9 vs 257.5 50 mg Once a Day · wk 48 · n 411 · Phase 3 · secondary NCT01227824
  • 248.8 vs 230.7 wk 48 · n 248 · Phase 3 · secondary NCT01910402
  • 224.1 vs 239.8 50 mg Once a Day · wk 40 · n 411 · Phase 3 · secondary NCT01227824
  • 230.7 vs 191.4 wk 36 · n 248 · Phase 3 · secondary NCT01910402
  • 223.4 vs 241.3 50 mg Once a Day · wk 32 · n 411 · Phase 3 · secondary NCT01227824
  • 199.3 vs 204.2 50 mg Once a Day · wk 24 · n 411 · Phase 3 · secondary NCT01227824
  • 200.6 vs 163 wk 24 · n 248 · Phase 3 · secondary NCT01910402
  • 322.6 vs 286 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 315.2 vs 272.1 50 mg plus 600/300 mg once daily · wk 84 · n 414 · Phase 3 · secondary NCT01263015
  • 349.3 vs 298.9 50 mg plus 600/300 mg once daily · wk 108 · n 414 · Phase 3 · secondary NCT01263015
  • 306.1 vs 269.6 50 mg plus 600/300 mg once daily · wk 72 · n 414 · Phase 3 · secondary NCT01263015
  • 347 vs 311 50 mg plus 600/300 mg once daily · wk 120 · n 414 · Phase 3 · secondary NCT01263015
  • 271.3 vs 235.3 50 mg plus 600/300 mg once daily · wk 60 · n 414 · Phase 3 · secondary NCT01263015
  • 377.9 vs 327.2 50 mg plus 600/300 mg once daily · wk 132 · n 414 · Phase 3 · secondary NCT01263015
  • 378.5 vs 331.6 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 267.5 vs 209.5 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · secondary NCT01263015
  • 379.5 vs 333.3 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 265.5 vs 216.2 50 mg plus 600/300 mg once daily · wk 40 · n 414 · Phase 3 · secondary NCT01263015
  • 250.5 vs 208.1 50 mg plus 600/300 mg once daily · wk 32 · n 414 · Phase 3 · secondary NCT01263015
  • 216.9 vs 177.8 50 mg plus 600/300 mg once daily · wk 24 · n 414 · Phase 3 · secondary NCT01263015
  • 264.7 vs 253.8 wk 96 · n 301 · Phase 3 · secondary NCT02831673
  • 272 vs 264.6 wk 96 · n 318 · Phase 3 · secondary NCT02831764
  • 265 vs 230 wk 96 · n 350 · Phase 2/3 · secondary NCT02259127
  • 311 vs 230 wk 96 · n 154 · Phase 2/3 · secondary NCT02259127
  • 228 vs 230 wk 96 · n 196 · Phase 2/3 · secondary NCT02259127
  • 222.2 vs 217.7 wk 48 · n 356 · Phase 3 · secondary NCT02831673
  • 301.8 vs 303.2 wk 144 · n 270 · Phase 3 · secondary NCT02831673
  • 225.7 vs 217.2 wk 48 · n 360 · Phase 3 · secondary NCT02831764
  • 301.7 vs 296.6 wk 144 · n 296 · Phase 3 · secondary NCT02831764
  • 192.2 vs 175.1 wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 188.8 vs 163.2 wk 24 · n 360 · Phase 3 · secondary NCT02831764
  • 72 vs 230 wk 96 · n 42 · Phase 2/3 · secondary NCT02259127
  • 39 vs 28 wk 48 · n 40 · Phase 3 · secondary NCT02263326
  • 88 vs 75 wk 24 · n 65 · Phase 2 · secondary NCT03991013
  • 111 vs 101 wk 24 · n 52 · Phase 2 · secondary NCT03851588
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety

Coverage. Cabotegravir/rilpivirine (Cabenuva): 13 of 13 rows · Dolutegravir: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCabotegravir/​rilpivirine (Cabenuva)
Rows use multiple source trials
Dolutegravir
Rows use multiple source trials
CD4+
absolute change · cells/uL
Induction
142.2 vs 135.5 Efavirenz cells/uL @ 16wk30 mga,b,c,d
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
148.3 vs 135.5 Efavirenz cells/uL @ 16wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
159.3 vs 135.5 Efavirenz cells/uL @ 16wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
214.7 vs 174.1 EFV/TDF/FTC cells/uL @ 16wk50 mg plus 600/300 mg once dailyb,c,d
NCT01263015 · Phase 3 · combination · HIV · phase 3
2 other source trials
155.1 vs 173 RTG cells/uL @ 16wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
76.5 vs 70 placebo cells/uL @ 16wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
CD4+
absolute change · cells/uL
No placebo or comparator arm
348.6 cells/uL @ 180wk30 mga,b,c,e
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
384.2 cells/uL @ 180wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
338 cells/uL @ 180wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
170.5 cells/uL @ 180wk50 mg BIDb,c,e
NCT01328041 · Phase 3
CD4+ Cell
event count · cells/uL
Maintenance
750 vs 906.8 CAB 30 mg+ABC/3TC cells/uL @ 96wkIM-Q4Wa,b,c
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
748.6 vs 906.8 CAB 30 mg+ABC/3TC cells/uL @ 96wkIM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
732.8 vs 711.5 DTG + TDF/FTC cells/uL @ 96wkb,c
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
734.9 vs 739.9 DTG + TDF/FTC cells/uL @ 96wk
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA
absolute change · log
Induction
-2.659 vs -2.602 Efavirenz log @ 16wk30 mga,b,c,d
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
-2.815 vs -2.602 Efavirenz log @ 16wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-2.823 vs -2.602 Efavirenz log @ 16wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-3.03 vs -2.98 EFV/TDF/FTC log @ 16wk50 mg plus 600/300 mg once dailyb,c,d
NCT01263015 · Phase 3 · combination · HIV · phase 3
3 other source trials
-2.917 vs -2.943 RTG log @ 16wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.86 vs -2.71 DRV + RTV log @ 16wk50 mg once daily
NCT01449929 · Phase 3
-1.48 vs -2.24 placebo log @ 16wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
HIV-1 RNA
absolute change · log
Maintenance
-2.89 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q4Wa,b,c
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
-2.77 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
-2.99 vs -3.06 EFV/TDF/FTC log @ 96wk50 mg plus 600/300 mg once dailyb,c
NCT01263015 · Phase 3 · combination · HIV · phase 3
1 other source trial
-2.938 vs -2.901 RTG log @ 96wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
HIV-1 RNA
absolute change · log
No placebo or comparator arm
-2.628 log @ 180wk30 mga,b,c,e
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
-2.767 log @ 180wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-2.747 log @ 180wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-2.425 log @ 180wk50 mg BIDb,c,e
NCT01328041 · Phase 3
HIV-1 RNA Less Than 400 Copies
responder rate · % of participants
Maintenance
85% (n=60) vs 73% (n=62) Efavirenz @ 48wk30 mga,b,c,e
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
89% (n=61) vs 73% (n=62) Efavirenz @ 48wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=60) vs 73% (n=62) Efavirenz @ 48wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
92% (n=242) vs 87% (n=242) DRV + RTV @ 48wk50 mg once dailyb,c,e
NCT01449929 · Phase 3
HIV-1 RNA Level
absolute value · log
Maintenance
1.59 vs 1.61 CAB 30 mg+ABC/3TC log @ 32wkIM-Q4Wa,b,c,e
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
1.6 vs 1.61 CAB 30 mg+ABC/3TC log @ 32wkIM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
2.72 vs 1.81 placebo log @ 32wk50 mg BIDb,c,e
NCT01568892 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 50 Copies
responder rate · % of participants
No placebo or comparator arm
100% (n=115) @ 130wkc,e,f
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=149) @ 432wkc,e,f
NCT01910402 · Phase 3 · registry result, not featured evidence
Dropout rate
13.6%g
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
8.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
13.1%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
6.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
11.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
1.3%CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
15.6%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
11.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
13.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
15.2%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
17.4%50 mg plus 600/300 mg once dailyh
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
26%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
13.6%50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
31.1%50 mg BID
NCT01328041 · Phase 3
8.5%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
10.7%
NCT04585737 · Phase 4 · registry result, not featured evidence
25.6%Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
13.1%Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
—DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
17.6%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
—DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
16.2%DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
11.4%DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
7.8%Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
4.7%Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
15.4%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
0%50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
0%Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
0%Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
23.9%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
0%50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
6.7%50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
1.5%
NCT03991013 · Phase 2 · registry result, not featured evidence
3.8%
NCT03851588 · Phase 2 · registry result, not featured evidence
—Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—g
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
5.7%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
3.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
4.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
1.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
1.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
4.9%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
3.1%50 mg plus 600/300 mg once dailyh
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
2.9%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
2.1%50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
3.8%50 mg BID
NCT01328041 · Phase 3
—
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
—
NCT04585737 · Phase 4 · registry result, not featured evidence
—Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
—Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
—DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
4%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
—DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
2.8%DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
2.8%DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
—Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
—
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
7.7%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
—50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—
NCT01837277 · Phase 2/3 · registry result, not featured evidence
—50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
—50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
—
NCT03991013 · Phase 2 · registry result, not featured evidence
—
NCT03851588 · Phase 2 · registry result, not featured evidence
—Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
Serious AEs
0%g
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
3.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
6.3%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
3.4%Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
4%
NCT04399551 · Phase 3 · registry result, not featured evidence
7.8%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
12.7%Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
10%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
26.5%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
11.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
0%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.4%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
17%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.1%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.6%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
15.2%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
12.5%Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
7.1%300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
15.7%50 mg plus 600/300 mg once dailyh
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
10%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
6.2%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg once daily
NCT01449929 · Phase 3
14.9%50 mg once daily
NCT01449929 · Phase 3
3.3%50 mg once daily
NCT01449929 · Phase 3
25.1%50 mg BID
NCT01328041 · Phase 3
9.9%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
8.1%
NCT04585737 · Phase 4 · registry result, not featured evidence
7.7%Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
8.2%Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
8.7%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
4.8%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
2.1%DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
10.4%DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
3.6%DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
10.8%DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
18%Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
18.1%Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
15.4%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
—50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
35.7%50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
26.2%Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
10%Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
14.9%Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
6.1%Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
9.8%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
6.9%50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
6.7%50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
3.1%
NCT03991013 · Phase 2 · registry result, not featured evidence
0%
NCT03851588 · Phase 2 · registry result, not featured evidence
0%Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
7.1%Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
g
injection site discomfort 13.6%
injection site pain 13.6%
fatigue 2.3%
NCT04982445 · Phase 4 · registry result, not featured evidence
show 40 more results
400 mg + 600 mg Q4W
injection site pain 32.3%
injection site nodule 9.7%
injection site induration 2.2%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 74.2%
injection site nodule 64.5%
injection site erythema 51.6%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 30.9%
injection site nodule 3.2%
injection site pruritus 2.1%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
injection site pain 65.2%
covid-19 17.9%
headache 12.5%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 60.6%
covid-19 19.4%
injection site induration 11.4%
NCT04542070 · Phase 3 · registry result, not featured evidence
Q2M
injection site pain 37.9%
covid-19 14.5%
arthralgia 0%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 80.2%
covid-19 18.4%
injection site induration 11.2%
NCT04399551 · Phase 3 · registry result, not featured evidence
injection site pain 55.7%
injection site discomfort 26.1%
fatigue 20%
NCT04001803 · Phase 3 · registry result, not featured evidence
creatinine renal clearance decreased 19.7%
lipase increased 11.3%
chills 7%
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 99.1%
injection site nodule 49.6%
nasopharyngitis 47%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 80%
injection site nodule 50%
nasopharyngitis 50%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 96.5%
nasopharyngitis 47%
injection site nodule 40%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 91.2%
injection site nodule 35.3%
covid-19 26.5%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
Q2M
injection site pain 74.4%
covid-19 33.3%
upper respiratory tract infection 17.8%
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
30 mg
headache 21.7%
nausea 18.3%
upper respiratory tract infection 13.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 26.4%
diarrhoea 13.2%
rash 11.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 31.9%
back pain 12.8%
oropharyngeal pain 12.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
headache 21.3%
diarrhoea 18%
nausea 18%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 21.8%
nausea 14.5%
bronchitis 10.9%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 27.5%
anxiety 11.8%
sinusitis 11.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
nausea 23.3%
headache 21.7%
diarrhoea 16.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
upper respiratory tract infection 17.3%
depression 9.6%
diarrhoea 9.6%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
diarrhoea 13%
nasopharyngitis 10.9%
gonorrhoea 8.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
dizziness 37.5% (placebo 0%)
dyspepsia 25% (placebo 0%)
headache 25% (placebo 0%)
NCT00920426 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain 0% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood bilirubin increased 0% (placebo 50%)
NCT00920426 · Phase 2 · registry result, not featured evidence
30 mg
atrioventricular block first degree 7.7%
decreased appetite 7.7%
headache 7.7%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
aspartate aminotransferase increased 50%
blood creatine phosphokinase increased 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site nodule 55.6%
injection site erythema 44.4%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site haemorrhage 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 72.7%
injection site pain 72.7%
injection site induration 45.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site induration 100%
injection site pain 100%
injection site bruising 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 75%
headache 37.5%
injection site swelling 37.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
catheter site bruise 50%
injection site erythema 50%
injection site induration 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 94.4%
headache 77.8%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 100%
injection site pruritus 87.5%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
injection site erythema 100%
injection site pain 100%
injection site warmth 88.9%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
accident 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site swelling 70%
headache 60%
NCT04484337 · Phase 1 · registry result, not featured evidence
30 mg
blood creatine phosphokinase increased 6.7%
contusion 6.7%
body temperature increased 0%
NCT03149848 · Phase 1 · registry result, not featured evidence
300 mg + 30 mg
body temperature increased 7.1%
headache 7.1%
hyperkeratosis 7.1%
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
50 mg plus 600/300 mg once dailyh
diarrhoea 22.7%
nasopharyngitis 20.8%
insomnia 17.9%
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 31 more results
50 mg Once a Day
nausea 14.6%
diarrhoea 14.1%
headache 13.6%
NCT01227824 · Phase 3 · HIV · phase 3
50 mg Once a Day
upper respiratory tract infection 8%
syphilis 7.1%
viral upper respiratory tract infection 7.1%
NCT01227824 · Phase 3 · HIV · phase 3
50 mg once daily
diarrhoea 17.8%
headache 16.5%
nausea 16.5%
NCT01449929 · Phase 3
50 mg once daily
viral upper respiratory tract infection 4.1%
gastroenteritis 2.4%
asthenia 1.6%
NCT01449929 · Phase 3
50 mg BID
diarrhoea 22.4%
cough 15.8%
nausea 14.2%
NCT01328041 · Phase 3
insomnia/nightmares 3.9%
alopecia 2%
itching/rash/prurigo 2%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
nausea 4.7%
fatigue 4%
diarrhea 3.4%
NCT04585737 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 8.7%
headache 8.1%
urinary tract infection 6%
NCT01910402 · Phase 3 · registry result, not featured evidence
nausea 18.5%
headache 11.7%
diarrhoea 9.3%
NCT01910402 · Phase 3 · registry result, not featured evidence
covid-19 6.9%
suspected covid-19 3.4%
headache 3%
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
headache 14.3%
diarrhoea 14%
nasopharyngitis 13.8%
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
covid-19 6%
syphilis 4%
respiratory tract infection viral 3.2%
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 13.6%
upper respiratory tract infection 13.1%
nasopharyngitis 12.2%
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
creatinine renal clearance decreased 83.9%
blood creatinine increased 78.3%
haemoglobin decreased 3.7%
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
creatinine renal clearance decreased 89.8%
blood creatinine increased 83.3%
haemoglobin decreased 9.3%
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
grade 3 bilirubinemia 0%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
50 mg OD
headache 53.8%
upper respiratory tract infection 38.5%
diarrhoea 30.8%
NCT01499199 · Phase 3 · registry result, not featured evidence
50mg BID
diarrhoea 21.4% (placebo 12.5%)
headache 21.4% (placebo 6.3%)
lymphadenopathy 21.4% (placebo 0%)
NCT01568892 · Phase 3 · registry result, not featured evidence
cns disturbances 0%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
50 mg od
low haemoglobin 6.9%
NCT02245022 · Phase 2/3 · registry result, not featured evidence
50 mg BID
abnormal loss of weight 10%
blood pressure increased 10%
headache 10%
NCT05630872 · Phase 2 · registry result, not featured evidence
acute psychosis 1.5% (placebo 0%)
incident pulmonary tuberculosis 1.5% (placebo 0%)
acute kidney injury 0% (placebo 3.1%)
NCT03991013 · Phase 2 · registry result, not featured evidence
insomnia 5.7% (placebo 0%)
NCT03851588 · Phase 2 · registry result, not featured evidence
haemoglobin decreased 33.3%
alanine aminotransferase increased 16.7%
aspartate aminotransferase increased 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 50%
alanine aminotransferase increased 16.7%
blood bilirubin increased 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 83.3%
neutrophil count decreased 50%
acne infantile 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 42.9%
blood bilirubin increased 35.7%
dermatitis diaper 21.4%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 56.3%
neutrophil count decreased 31.3%
blood bilirubin increased 25%
NCT05406583 · Phase 1 · registry result, not featured evidence
hypokalaemia 71.4% (placebo 71.4%)
hypoglycaemia 42.9% (placebo 71.4%)
vivid dreams 28.6% (placebo 0%)
NCT04771754 · Phase 1 · registry result, not featured evidence
hypokalaemia 62.5% (placebo 71.4%)
cold 25% (placebo 14.3%)
bloating 12.5% (placebo 0%)
NCT04771754 · Phase 1 · registry result, not featured evidence
50mg/25mg
headache 6.3%
vessel puncture site bruise 6.3%
vomiting 6.3%
NCT03984838 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context differs: pooled versus combination.
  5. eTreatment context has not been resolved for both arms.
  6. fAssessment timepoints differ: 130 weeks versus 432 weeks.
  7. gPopulation comparability has not been reviewed for these studies.
  8. hPopulation comparability has not been reviewed for 39 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cabotegravir/rilpivirine (Cabenuva)

HIV-1 RNA Less Than 50 Copies Per 100% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
99% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
90% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA Ge50 Copies 0% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
1.1% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
2.2% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
Virologic Failure 0% (n=93)400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
0% (n=115)
NCT04001803 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 99% (n=430) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence
show 4 more results
96% (n=430) @ 8.67wk
NCT04399551 · Phase 3 · registry result, not featured evidence
93% (n=430) @ 17.33wk
NCT04399551 · Phase 3 · registry result, not featured evidence
86% (n=430) @ 34.67wk
NCT04399551 · Phase 3 · registry result, not featured evidence
87% (n=430) @ 52wk
NCT04399551 · Phase 3 · registry result, not featured evidence
Virologic Failure 0% (n=430) @ 4.33wk
event count · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 6 more results
0% (n=430) @ 8.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 17.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 26wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 34.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0.2% (n=430) @ 43.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
0% (n=430) @ 52wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
Virologic Failure 0.07 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.04 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Treatment Failure 0.14 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 Cumulative probability @ 44wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 0.13 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.12 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 9.9% (n=71) @ 44wk
event count · % of participants
No placebo or comparator arm
HIV-1 RNA ≥ 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
Virologic Response 50 Copies Snapshot 81.7% (n=71) @ 44wk
responder rate · % of participants
No placebo or comparator arm
HIV-1 RNA < 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
Virologic Failure 0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q4W
event count · % of participants
Maintenance
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 6 more results
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0.9% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0.9% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
1.7% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
1.1% (n=90) vs 0% (n=7) DTG + RPV*Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
HIV-1 RNA Less Than 50 Copies 99% (n=115) vs 98% (n=56) CAB 30 mg+ABC/3TC @ 0wkIM-Q4W
responder rate · % of participants
Maintenance
HIV-1 RNA<50 c/mL, Day 1
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
95% (n=115) vs 98% (n=56) CAB 30 mg+ABC/3TC @ 0wkIM-Q8W
HIV-1 RNA<50 c/mL, Day 1
NCT02120352 · Phase 2 · registry result, not featured evidence · combination

+ 161 further endpoints in the CSV export.

Dolutegravir

Time to Viral Suppression 0.92 vs 2.79 DRV + RTV months50 mg once daily
time to event · months
NCT01449929 · Phase 3 · converted to months from 28 days as posted
show 2 more results
0.92 vs 2.76 EFV/TDF/FTC months*50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3 · converted to months from 28 days as posted
0.95 vs 0.95 DTG + TDF/FTC months*
NCT02831764 · Phase 3 · registry result, not featured evidence · combination · converted to months from 29 days as posted
Virologic Failure 2.7% (n=414) vs 1.9% (n=419) EFV/TDF/FTC50 mg plus 600/300 mg once daily
event count · % of participants
ACTG virologic failures
NCT01263015 · Phase 3 · combination · HIV · phase 3 · converted to % from 11 Participants as posted
Symptom Bother -1.818 vs -1.246 EFV/TDF/FTC score50 mg plus 600/300 mg once daily
absolute change · score
NCT01263015 · Phase 3 · combination · HIV · phase 3
HIV-1 RNA Less Than 50 80.8% (n=411) vs 76.4% (n=411) RTG @ 96wk50 mg Once a Day
event count · % of participants
Maintenance
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 332 Participants as posted
HIV-1 RNA Less Than 400 89.8% (n=411) vs 86.6% (n=411) RTG @ 48wk50 mg Once a Day
event count · % of participants
Maintenance
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 369 Participants as posted
show 1 more result
82.2% (n=411) vs 78.1% (n=411) RTG @ 96wk*50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 338 Participants as posted
CD4+ 80.1 vs 75.6 DRV + RTV cells/uL @ 4wk50 mg once daily
absolute change · cells/uL
Induction
CD4+ cell count, Week 4, n=237, 236
NCT01449929 · Phase 3
CD4+ 126.9 vs 118.8 DRV + RTV cells/uL @ 8wk50 mg once daily
absolute change · cells/uL
Induction
CD4+ cell count, Week 8, n=236, 236
NCT01449929 · Phase 3
CD4+ 135.2 vs 131.8 DRV + RTV cells/uL @ 12wk50 mg once daily
absolute change · cells/uL
Induction
CD4+ cell count, Week 12, n=234, 228
NCT01449929 · Phase 3
CD4+ 156.8 vs 146.1 DRV + RTV cells/uL @ 16wk50 mg once daily
absolute change · cells/uL
Induction
CD4+ cell count, Week 16, n=227, 227
NCT01449929 · Phase 3
CD4+ 165.1 vs 164.3 DRV + RTV cells/uL @ 24wk50 mg once daily
absolute change · cells/uL
Maintenance
CD4+ cell count, Week 24, n=233, 227
NCT01449929 · Phase 3
CD4+ 206.1 vs 186.5 DRV + RTV cells/uL @ 36wk50 mg once daily
absolute change · cells/uL
Maintenance
CD4+ cell count, Week 36, n=232, 218
NCT01449929 · Phase 3
CD4+ 243.8 vs 215.4 DRV + RTV cells/uL @ 48wk50 mg once daily
absolute change · cells/uL
Maintenance
CD4+ cell count, Week 48, n=227, 212
NCT01449929 · Phase 3

+ 85 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Dolutegravir's landscape